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Abstract of Dissertation

MODULATION OF THE ADRENAL MEDULLARY RESPONSE TO
STRESS BY ESTRADIOL IN THE FEMALE RAT
The present study has established that physiological concentrations of estradiol can modulate
stress-induced increases in plasma epinephrine (EPI). In anesthetized female rats, insulininduced hypoglycemia (0.25 U/kg) increased plasma EPI concentration to a significantly greater
extent in 14-day ovariectomized (OVEX) rats compared to sham-operated controls. In 17βestradiol (E2)-replaced OVEX rats, the hypoglycemia-induced rise in plasma EPI was
significantly reduced compared to OVEX rats. This suppression was due to both decreased
adrenal medullary output and increased clearance of EPI. Adrenal venous EPI concentration
was significantly reduced in OVEX+E2 rats, suggesting that EPI secretion from the adrenal
medulla was decreased by E2 replacement. The underlying mechanism(s) of this apparent E2mediated reduction in secretion could not be established since 1) the expression levels of the
biosynthetic enzymes tyrosine hydroxylase and phenylethanolamine N-methyltransferase were
not affected in OVEX+E2 rats, suggesting that EPI biosynthesis is similar in these and OVEX
rats; and 2) agonist-induced increases in intracellular Ca2+ were identical in isolated adrenal
medullary chromaffin cells exposed to E2 (10 nM) or vehicle for 48 hr, suggesting that stimulus
secretion coupling is unaffected by E2 treatment. In contrast, plasma clearance of EPI was
significantly increased in OVEX+E2 rats.
Although 48 hr exposure to E2 had no effect on intracellular signaling in chromaffin cells,
acute (3 min) exposure to micromolar concentrations of E2 dose-dependently and reversibly
inhibited agonist-induced Ca2+ transients. Consistent with this observation, acute (30 min)
infusions of E2 also significantly reduced the insulin-induced increase in plasma EPI in OVEX
rats. These data demonstrate that physiological levels of circulating E2 can modulate
hypoglycemia-induced increases in plasma EPI. This effect appears to be mediated by the
steroid’s influence on adrenal medullary EPI output and plasma EPI clearance; however the
mechanism(s) underlying these E2-mediated modulations remain undetermined. This study has
also established that acute exposure to supra-physiological levels of E2 can suppress
hypoglycemia-induced increases in plasma EPI, due at least in part to inhibition of stimulussecretion coupling.
Key Words: Estradiol, Stress, Adrenal Medulla, Epinephrine, Chromaffin Cell
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Chapter 1: Introduction
Estrogen
Estrogen and progesterone are the main steroid hormones synthesized by and
secreted from the ovary. Estradiol, the most biologically active form of estrogen, is
produced by the granulosa cells of antral follicles and is responsible for various actions
throughout the reproductive system. For example, estradiol induces the proliferation of
granulosa cells in the ovary, the epithelial and stromal layers in the uterus, and the
epithelium in the vagina.

The development of the lactiferous duct system in the

mammary glands is also dependent upon the presence of estradiol (Kacsoh, 2000).
Typically, estradiol acts through traditional steroid receptor mechanisms.
Intracellular estrogen receptors, which act as transcription factors, bind estradiol and
dimerize in the cytoplasm of the target cell. The estrogen receptor dimer translocates to
the nucleus and binds estrogen-responsive elements located in the promoter region of
estrogen-responsive genes, thereby regulating transcription of these genes. There are
at least two subtypes of estrogen receptors, the classic estrogen receptor alpha (ERα),
and the more recently discovered estrogen receptor beta (ERβ). Although ERα and
ERβ share a high degree of sequence homology, they are the product of two different
genes and exhibit tissue/cell-specific expression and action (Matthews and Gustafsson,
2003 for review). In addition to acting via this traditional, relatively slow-onset genomic
transcription/translation signaling pathway, several studies have demonstrated that
estrogens can also initiate rapid activation of G-protein-coupled receptor signaling
systems, perhaps by binding to distinct pools of estrogen receptors which locate to
caveolae regions of the plasma membrane (Hall et al., 2001; Nadal et al., 2001; Levin,
2002). For example, acute exposure to estradiol stimulates a rise in intracellular Ca2+,
P

P

and activates the protein-kinase A and protein-kinase C signaling pathways in female
colon cells, while in smooth muscle cells and atrial/ventricular myocytes, short-term
estradiol exposure attenuates voltage-dependent Ca2+ current (Levin 1999 for review;
P

Kelly and Levin, 2001).

1

P

Extra-Reproductive Effects of Estrogen
Although primarily regarded as the female sex hormone, estradiol acts beyond
the scope of the reproductive axis at various sites, including bone, liver, kidney, brain,
heart, and vasculature. For instance, estradiol induces elongation of bone, the closure
of the epiphyseal plates, and prevents bone resorption. This latter benefit on bone
remodeling is lost at menopause, a time in normal female aging when estradiol
secretion declines. This permanent decrease in circulating estradiol concentration is
often accompanied by increased osteoporosis and bone fragility in postmenopausal
women (Lindsay, 1996).

Recent studies have shown that hormone replacement

therapies, which include estrogens, can decrease the incidence and severity of
osteoporosis in post-menopausal women (Lawrenson et al., 2005; Stevenson, 2005).
Several studies have shown that a number of health problems confronted by
older women can be linked to the deficiency of circulating estradiol after menopause.
For example, increases in the prevalence of heart disease and the incidence and
severity of hypertension in post-menopausal women are reduced by hormone
replacement therapy (Kannel et al., 1976; Pines et al., 1996; Prevlevic et al., 1997;
Wassertheil-Smoller et al., 2000). The mechanisms underlying these benefits are quite
diverse, and include estrogenic effects on lipid and lipoprotein metabolism and both
vascular reactivity and growth (Prevlevic et al., 1997; Dubey et al., 2001, 2004;
Mendelsohn et al., 2005).

Additionally, estradiol replacement also lessens the risk

and/or delays the onset of neurodegenerative conditions such as Alzheimer’s disease
(Henderson et al., 1996; Asthana et al., 1997; Kawas et al., 1997; Baum, 2005), and
provides cognitive benefits (see Gleason et al., 2005 for review) in post-menopausal
women.
Not all data are consistent with the concept that estrogen is protective against
these types of illnesses. While it is widely accepted that high doses of estradiol can be
harmful, increasing the risk of breast cancer, venous thrombosis, stroke, and pulmonary
embolism (Gillum et al., 2000), clinicians with the Women’s Health Initiative (WHI), a
study which has enrolled more than 160,000 participants overall, reported in 2002 that
post-menopausal women receiving lower dose hormone replacement therapy (a
combination of estrogen and progesterone) also have a higher risk for heart disease,

2

stroke and blood clots compared to post-menopausal women receiving placebo
treatment (Pradhan et al.)

In 2004, it was reported that post-menopausal women

receiving estrogen-only therapy are also at a greater risk for blood clots, stroke and
dementia than those in the placebo control group (Anderson et al.). In light of these
reports, doctors halted all hormone and estrogen-only treatment studies in the WHI. It
should be noted, however, that the estrogens used in these replacement therapies were
conjugated equine estrogens, which can adversely affect the liver (Turgeon et al.,
2004), that the therapies were given orally, which can affect hemostasis (Scarabin et al.,
1997; Luyer et al., 2001), and that the women who were enrolled in these studies were
well past the onset of menopause (average age of 63 and 65 years old) when they
began the therapies.

Given these cohorts and the fact that the levels of estrogen

administered orally in hormone and estrogen replacement therapies are typically nonphysiologic, even in low-dose regimes, the effects of physiologic levels of estradiol in
younger individuals have remained undefined.
Several basic science studies have investigated the effects of estradiol in more
controlled paradigms. Dubal and Wise (2001) have demonstrated that both estrous and
pro-estrous concentrations of estradiol replacement in ovariectomized rats protects
against infarct injury during ischemic stroke in both young and middle aged rats. In
these studies, estradiol protected against stroke-induced injury by inhibiting infarctinduced cell death. High doses of estradiol are also protective against ischemic brain
injury, as demonstrated by Yang et al. (2000). In these studies, the injection of estradiol
up to 3 hours after the initial injury attenuated infarct-induced damage by modulating
both cerebral blood flow and the production of nitric oxide.
Beneficial/protective effects of estradiol have also been demonstrated in the
cardiovascular system.

Chronic estrogen treatment lowers blood pressure in both

transgenic and spontaneously hypertensive rats (Brosnihan et al., 1997; Crofton and
Share, 1997; Li et al., 1997). Pressor responses to phenylephrine are also reduced in
chronically estradiol-treated ovariectomized rats, while indices of baroreflex sensitivity
are greater than in vehicle treated controls (He et al., 1998). This latter conclusion is
supported by a study in conscious mice, which demonstrated that estradiol facilitates
baroreflex function, perhaps by modulating angiotensin II-mediated effects on the

3

cardiovascular system (Pamidimukkala et al., 2003). He et al. (1998) also demonstrated
that an acute, intravenous injection of estradiol lowers heart rate, and renal and
splanchnic nerve activity in ovariectomized rats compared to vehicle-treated controls.

Estrogen and Stress
Stress responses are affected by estradiol in a variety of manners. For example,
post-menopausal women have increased behavioral responses to mental stress
compared to pre-menopausal women, and estrogen therapy attenuates this increase
(Lindheim et al., 1992; Owens et al., 1993).

These conclusions are supported by

studies in experimental animals, which have shown that physiological concentrations of
estradiol reduce anxiety and depressive behavior in rats subjected to open field,
elevated plus maze, and forced swim tests (Lunga and Herbert, 2004; Walf and Frye,
2005).

The activity of the hypothalamic-pituitary-adrenal axis (HPA axis) is also

modulated by the presence of estradiol. Clinical studies have shown that cortisol levels
are significantly decreased after menopause and are restored with estrogen
replacement therapy (Helgason et al., 1981). In the rat, basal plasma levels of both
ACTH and corticosterone are lower in ovariectomized rats than in intact controls and
estradiol replacement returns both hormones to control levels (Burgess and Handa,
1992, Seale et al., 2004, Lunga and Herbert, 2004, Serova et al., 2005). In contrast,
immobilization

stress-induced

increases

in

plasma

ACTH

concentrations

are

significantly lower in estradiol-replaced ovariectomized rats than in their controls
(Serova et al., 2005).

Adrenal Medullary Response to Stress
As first proposed by Cannon in 1934, it is now well established that the adrenal
gland is vital in the maintenance of overall body homeostasis during times of stress.
Stressors such as trauma (Hammond et al., 1956; Barton et al, 1981), hypotension (Lilly
et al., 1982; Bereiter et al., 1984), cold (Gordon et al., 1966; LeBlanc et al., 1967;
Kanayama et al., 1999), hypoxia (Fowler et al., 1961; Bloom et al., 1977), and
hypoglycemia (Niijma, 1989) result in a marked increase in both adrenal medullary
catecholamine and adrenocortical glucocorticoid secretion, resulting in adaptation to the
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stressor by eliciting diverse cardiovascular, metabolic, and immunomodulatory effects
(Axelrod and Reisine, 1984; Becker, 1986; Ewbank 1992). Furthermore, tolerance to
such stressors as exercise (Winder et al., 1987), hemorrhage (Bond and Johnson,
1984), and hypoxia (Nahas et al., 1954) is severely reduced in adrenalectomized and/or
adrenal de-medullated animals.
The principal catecholamines, epinephrine (EPI) and norepinephrine (NE) are
synthesized by and released from adrenal medullary chromaffin cells, which are
considered functionally similar to postsynaptic sympathetic neurons. However, these
cells do not have axons, and therefore function in a more endocrine manner by
secreting

epinephrine

and

norepinephrine

directly

into

the

blood

stream.

Catecholamine biosynthesis occurs within the cells through a series of enzymatic
reactions, with the conversion of tyrosine to dihydroxyphenylanine (DOPA) by tyrosine
hydroxylase as the initial and rate-limiting step. DOPA is then converted to dopamine
(DA) by dopa decarboxylase (DDC) and DA is converted to NE by dopamine-betahydroxylase (DBH).

Lastly, NE is converted to EPI by phenyl-ethanolamine-N-

methyltransferase (PNMT).
It is well established that there are two separate populations of chromaffin cells
(Moro et al., 1990) characterized by the presence or absence of this latter enzyme. The
ratio of PNMT containing (EPI secreting) cells to non-PNMT containing (NE secreting)
cells is species dependent. For example, the ratio of EPI secreting to NE secreting cells
in the rat adrenal medulla is approximately 4:1 (Verhofstad et al., 1985; Tomlinson et
al., 1987), while the ratio is approximately 1:1 in the pig (Verhofstad et al., 1989). In
humans, approximately 80% of adrenal medullary chromaffin cells are EPI secreting
while just 20% are NE (Vollmer, 1996 for review).
Catecholamines are stored in vesicles until their release, which occurs when a
stress-induced increase in splanchnic nerve activity stimulates secretion from the
chromaffin cell.

Mechanistically, acetylcholine, released from the adrenal nerve (a

branch of the splanchnic nerve), induces sodium (Na+) and calcium (Ca2+) influx via
nicotinic receptor-operated ion channels (Wada et al., 1985).

The resultant

depolarization activates voltage gated Ca2+ channels and results in a transient rise in
intracellular free Ca2+ concentration, which is the primary trigger for catecholamine
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exocytosis (Kilpatrick et al, 1982). The rise in intracellular Ca2+ can also increase the
P

P

activity of tyrosine hydroxylase, the rate-limiting enzyme in the biosynthetic cascade and
therefore enhance catecholamine biosynthesis, which allows chromaffin cells the ability
to maintain catecholamine stores in cases of increased secretion and maintain the
cellular catecholamine content at a relatively constant amount, a process described as
stimulus-synthesis-secretion coupling (Wakade et al., 1988; Malhotra et al., 1989).

Estradiol and the Adrenal Medullary Response to Stress
While the response of the HPA axis to a stressor is usually enhanced by
estradiol,

clinical

studies

indicate

that

stress-induced

increases

in

plasma

catecholamines are lower in post-menopausal women receiving estrogen replacement
therapy (Del Rio et al., 1993; Komesaroff et al., 1999; Ceresinsi et al., 2000; Sandoval
et al., 2003). Despite these persuasive clinical observations, the mechanism(s)
underlying this estrogen-dependent suppression of stress-evoked catecholamine
responses, and more specifically the effects of normal circulating levels of estrogen on
this response, have not been convincingly established. Conclusions from studies in the
rat are contradictory and may be dependent upon several factors, including the type of
stressor utilized and the age, weight, and strain of the rat. For example, the
hypoglycemia-induced increase in plasma catecholamine concentration is attenuated in
female rats compared to weight-matched males (Drake et al., 1998), while foot-shock
evoked increases are enhanced in females compared to age-matched males
(Weinstock et al, 1998).
The prospect that estradiol can affect adrenal medullary function is supported by
a report which identified ERα immunoreactivity in chromaffin cells of the female but not
male rat adrenal gland (Green et al., 1999). However, information regarding estrogen
effects on catecholamine biosynthesis is both limited and inconclusive. For example, it
has been reported that daily injections of a high dose of estradiol for 3 days increases
adrenal medullary epinephrine content in ovariectomized rats (Fernandez-Ruiz et al.,
1988), and that 10 days of estrogen treatment in intact female rats increases the activity
of adrenal tyrosine hydroxylase (TH), the rate limiting enzyme in the biosynthetic
cascade (Kohler et al., 1975). In contrast, TH activity was reported to be unaffected by
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estrogen treatment in ovariectomized rats (de Miguel et al., 1989).

More recently,

Serova et al. (2005) have demonstrated that TH mRNA levels are increased in the
adrenal medulla of non-stressed, estradiol-treated ovariectomized rats compared to
vehicle-treated controls. Conversely, the treatment paradigm utilized in this study also
inhibited the stress-induced increase in TH mRNA levels seen in the control group.
It is now accepted that in addition to acting via traditional steroid-receptor
signaling pathways, members of the steroid receptor superfamily, can rapidly affect cell
function (Losel et al., 2003 for review).

Previous studies from our laboratory have

identified crosstalk between the adrenal stress hormones, establishing that both acute
and long-term exposure to physiologic concentrations of glucocorticoids can modulate
catecholamine stimulus-secretion pathways in vitro in both rat and pig chromaffin cells.
Notably, these effects were found to be diametrically opposite: long-term exposure to
physiologic concentrations of the synthetic glucocorticoid dexamethasone potentiates
voltage-gated Ca2+
intracellular Ca
P

2+
P

channel current, consequently potentiating
P

P

transients (Fuller et al., 1997a,b),

agonist-induced

while acute exposure to

dexamethasone dose-dependently attenuates voltage-gated Ca2+ channel current and
P

P

the subsequent intracellular Ca2+ transient (Wagner et al., 1999).
P

P

Several in vitro studies have demonstrated that relatively high concentrations of
estrogen can also acutely and therefore, presumably non-genomically, modulate
adrenal medullary function. For example, in the isolated perfused rat adrenal gland,
nicotinic agonist-induced catecholamine secretion is suppressed within minutes of
exposure to 17α-estradiol (Park et al., 1996). Similarly, short-term exposure to 17αestradiol suppresses secretory responses to both nicotinic agonists and to direct
depolarization with KCl in isolated perfused bovine and feline adrenal glands (Lopez et
al., 1991). Mechanistically, the KCl data combined with the fact that steroid treatment
also suppresses agonist-induced
P

45

Ca2+ uptake in isolated bovine chromaffin cells,
P

P

P

suggests that the primary site of estradiol action may be the voltage-gated Ca2+
P

channel. Consistent with this concept, Kim et al., (2000) have demonstrated that shortterm exposure to 17β-estradiol suppresses KCl-induced [3H] nor-epinephrine secretion
P

P

and intracellular Ca2+ transients in the PC-12 cell line, an established model of the
P

P

medullary chromaffin cell. At least in this model, channel-selective antagonist studies

7

P

demonstrated that estrogen inhibited both L- and N-type voltage-gated Ca2+ channels.
Evidence in favor of an acute suppressive effect of estradiol on catecholamine secretion
in vitro is not unanimous however. Dar and Zinder (1997) have reported that, compared
to the effects of progestins and androgens, estrogens in general have relatively little
effect on agonist-induced catecholamine secretion in bovine chromaffin cells. While the
rapid-onset effects of estradiol on catecholamine secretion described above are
consistent with a non-genomic mechanism of hormone action, it is not clear whether the
effects have physiological significance, since the concentrations of steroid used in all of
the these studies far exceeds normal plasma levels of estrogen in the rat (Smith et al.,
1975).
Based on these data that non-physiological levels of estrogen can modulate the
adrenal medullary response to stress in post-menopausal women and that acute
exposure to high levels of estradiol can affect stimulus-secretion coupling in the
chromaffin cell, the primary goal of the studies presented in this dissertation was to
specifically determine whether physiological levels of estradiol can affect stress-induced
increases in plasma catecholamine concentration. The working hypothesis to be tested
was that physiological concentrations of estradiol attenuate the stress-induced
increase in plasma epinephrine concentration by directly suppressing secretion
from the adrenal medullary chromaffin cell.

Copyright © Julye M. Adams 2005
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Chapter 2: Materials and Methods
Animals and Experimental Treatments
All animal protocols were approved by the University of Kentucky Institutional
Animal Care and Use Committee and utilized 12-14 week-old female Sprague-Dawley
rats. Animals were housed individually in a room with controlled temperature (24oC)
P

P

and light (14:10-h light-dark cycle) and given free access to food and water. Bilateral
ovariectomy (or sham-surgery) was performed under isoflurane anesthesia via two
small flank incisions.

For estradiol replacement, capsules containing either 17β-

estradiol or vehicle were implanted subcutaneously at this time. The implanted capsules
were made in accordance with previously published protocols (Wise et al., 1981; Dubal
et al., 2001), by injecting 0.07 mL of either 17β-estradiol (1 mg/mL; Sigma; St. Louis,
MO) or sesame oil into 30 mm lengths of SILASTIC brand tubing (0.062/0.125 in
inner/outer diameter; Dow Corning; Midland, MI). Each capsule was capped at both
ends with 5 mm wooden applicator sticks.
Uterine weight and the change in overall body weight 14 days after surgery are
listed in Table 2.1. Plasma estradiol concentrations measured 14 days after surgery are
displayed in Figure 2.1. Ovariectomized rats gained more overall body weight and had
significantly lower uterine weights and plasma estradiol concentrations than the shamoperated controls. Uterine weights and plasma estradiol concentrations were
significantly greater and changes in body weight were significantly reduced in the
estradiol-replaced group compared to the ovariectomized group. Estradiol replacement
produced plasma estradiol concentrations equivalent to those of sham rats during the
proestrous phase of the estrous cycle. Uterine weights and changes in body weight
also were not different between these two groups.

In Vivo Studies
The primary catecholamine secreted from the adrenal medulla is epinephrine
(EPI; Vollmer, 1996). Therefore, plasma EPI concentrations in response to stress were
determined in all treatment groups.
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Insulin-induced hypoglycemia was used as a stressor to assess the effects of
estradiol on increases in plasma EPI. This well established paradigm elicits consistent
increases in plasma EPI levels in both experimental animals (Vollmer et al., 1997;
Drake et al., 1998) and humans (Diamond et al., 1993; Davis et al., 2000).
A. Hypoglycemic-Stress Model
1. Measurement of Stress-Induced Plasma Epinephrine Concentrations
For these experiments, overnight-fasted rats were anesthetized with inactin (100
mg/kg, i.p.; Sigma) and following tracheotomy, the left femoral artery and femoral vein
were catheterized with PE 50 tubing. Core body temperature was maintained at 36.7oC
P

P

by heat pad/lamp, and blood pressure and heart rate were recorded with a Grass Model
7 polygraph (Grass Instruments Co.; Quincy , MA) for the duration of the experiment.
After a 30 min equilibration period, a baseline arterial blood sample (0.6 mL) was taken
and a bolus of insulin was injected via the femoral vein (Figure 2.2). Additional blood
samples were taken 30 and 60 min post-insulin. Blood volume was replaced with 0.9%
sterile saline. A small volume (10 µL) from each heparinized sample was used to
measure blood glucose concentrations by a OneTouch Ultra glucose monitoring system
(glucometer; Lifescan-Johnson & Johnson; Milpitas, CA), and the sample was
centrifuged and the plasma was stored at -80oC for later EPI analysis by enzyme-linked
P

immunosorbent assay (ELISA).

P

Preliminary experiments established that blood-

sampling performed in the absence of insulin-induced hypoglycemia did not increase
plasma epinephrine concentration above baseline (Figure 2.3).
Preliminary experiments also examined the effects of two concentrations of
insulin on plasma EPI concentration. Both 0.25 U/kg and 1.0 U/kg of insulin elicited
decreases in plasma glucose concentrations (∆ -67 ± 2.1% and >-76 ± 1.2%,
respectively) and increases in plasma EPI concentrations (5 fold and 30 fold,
respectively) after 30 min of hypoglycemia. (It should be noted that, in several rats, 1.0
U/kg of insulin lowered plasma glucose to below the detectable range (< 20 mg/dL) of
the glucometer after 30 min of hypoglycemia.)

Both the decrease in plasma glucose

and the increase in plasma EPI concentrations were significantly greater in the 1.0 U/kg
insulin-treated compared to the 0.25 U/kg insulin treated rats (Figure 2.4; P<0.01). After
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60 min, plasma glucose and EPI concentrations returned toward baseline in 0.25 U/kg
insulin-treated rats. Glucose and EPI concentrations in the 1.0 U/kg insulin-treated rats
did not differ after 60 min of hypoglycemia compared to 30 min, and were significantly
different than the 0.25 U/kg insulin-treated group at 60 min (P<0.01). All subsequent
experiments utilized the sub-maximal stress effects of the 0.25 U/kg dose of insulin to
determine the effects of estradiol on hypoglycemia-induced increases in plasma EPI
concentration.
2. Measurement of Adrenal Medullary Epinephrine Output
For these experiments, a method for the collection of adrenal venous blood
previously published by Vollmer et al. (2000) was modified for use with the basic
hypoglycemia protocol. After the femoral cannulations, a peritoneal incision was made
and the abdominal wall retracted to reveal the left kidney, adrenal gland, and
surrounding vasculature. Ligatures were tightened around the renal vein and artery just
proximal to the hilus of the kidney. A loose (non-tightened) ligature was placed around
the renal vein just distal to the vena-cava. Visible venous branches were either ligated
or cauterized so that only adrenal venous flow entered the renal vein. A bolus dose of
heparin (300 U/kg) was injected intravenously and a small length (9-10 mm) of capped
PE 50 tubing filled with heparinized saline was placed in the renal vein distal to the
adrenal vein branch. Insulin was injected after a 30 min equilibration period. After 24
min of hypoglycemia, the loose ligature at the vena cava was tightened and
renal/adrenal venous flow was allowed to backflow through the uncapped renal vein
catheter and was collected in a pre-weighed 1.5 mL microcentrifuge tube.

The

collection continued for 6 min and was weighed to quantify a flow rate which was used
to determine the adrenal medullary secretion rate. No arterial blood samples were
taken during these experiments.
3. Measurement of Sympathetic Nerve Activity (SNA)
The basic hypoglycemia model was modified in order to record renal nerve
activity in accordance with previously published methods (Randall et al., 1994; Brown et
al., 1999; Stocker et al., 2004). After the femoral cannulations, a retroperitoneal incision
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was made and the left kidney was retracted allowing the isolation of a sympathetic renal
nerve. After placing the nerve on a stainless steel wire electrode and covering both the
nerve and wire with a silicon-based impression material (Super-Dent Light, Darby
Dental Supply; Westbury, NY), the electrical signals from the nerve were obtained using
a high-impedance probe and were amplified (50,000) and band-pass filtered (between
30-3,000 Hz) by a Grass P511 differential amplifier. The data were digitized at 10,000
samples/sec using a Cache 486 microprocessor and Data Translation DT2821-F
analog-to-digital converter. Nerve signals were recorded for 20 min before and 60 min
after an insulin bolus. The raw nerve signal was full-wave rectified and integrated (1
sec time constant) using software developed by Dr. David Brown in Visual C++ (Figure
2.5). Background noise was determined by the average value of integrated voltage
over 5 min after a bolus injection of 1M KCl (3 mL/kg; i.v.) to euthanatize the rat. No
arterial blood samples were taken during these experiments.
Values for renal sympathetic nerve activity were measured as 1 min averages
every 5 min after the insulin bolus. This activity was expressed as a percent change
from an average baseline value that was calculated from 3 separate 1 min averages 10,
5, and 1 min before insulin. Background noise was subtracted from all 1 min averages
prior to calculating the percent change.
B. Measurement of Epinephrine Clearance
For these experiments, methods from Azoui et al. (1997) and Marker et al. (1998)
were modified (Figure 2.6) and rats were infused with 3 increasing doses of EPI for 30
min each, equaling a total infusion time of 90 min. Rats were anesthetized with inactin
(100 mg/kg, i.p.) and following tracheotomy, the left femoral artery and left and right
femoral veins were catheterized with PE 50 tubing. Core body temperature was
maintained at 36.7oC by heat pad/lamp and blood pressure and heart rate were
recorded with a Grass Model 7 polygraph for the duration of the experiment. After a 30
min equilibration period, a baseline arterial blood sample (0.6 mL) was taken and an
intravenous infusion of EPI (Sigma) was started at a rate of 600 pmol/kg/min. After 30
min of infusion, an arterial blood sample (0.6 mL) was taken and the EPI infusion rate
was increased to 1500 pmol/kg/min by change-out of the syringe on the infusion pump.
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This ensured that the infused volume over 30 min remained consistent for all doses. An
arterial blood sample was taken after 30 min and the EPI infusion rate was increased to
3000 pmol/kg/min. The last blood sample was taken 30 min later. Each heparinized
blood sample was centrifuged and plasma was stored at -80oC for later catecholamine
analysis by ELISA.

In Vitro Studies
A. Rat Adrenal Medullary Chromaffin Cells
1. Chromaffin Cell Isolation
Chromaffin cells were isolated from the adrenal medullae of 12-14 week-old
female Sprague-Dawley rats as previously described by Fuller et al. (1997a). Adrenal
glands were removed from CO2-euthanatized rats and submerged in warmed (37oC)
Hank’s balanced salt solution (HBSS 7.4). The adrenal medullae were dissected from
the cortical tissue and cut into four pieces and washed in HBSS. The tissue was then
suspended

in

Ca2+/Mg2+-free

HBSS

containing

0.3%

collagenase

D,

0.15%

hyaluronidase, and 0.02% DNase, and transferred to a spinner flask for digestion. The
medullae pieces were incubated at 37oC for approximately 30 min with gentle spinning
and with trituration by a fire polished glass pipette every 10 min to break up chunks of
tissue. The suspension was checked several times during the digestion for single cells,
30 min generally yielded a majority of healthy single cells. The cell suspension was
then filtered through a 200 µM screen into a 15 mL centrifuge tube and the cells were
washed in enzyme-free, Ca2+/Mg2+-free HBSS and centrifuged at 1500 rpm for 3 min.
The cells were resuspended in DMEM containing 10% fetal bovine serum, 40 mg/L
gentamicin, 100,000 U/L penicillin, 40,000 U/L nystatin, 4 g/L ascorbate, and 10 µM
cytosine arabinose. Aliquots of the cell suspension were allowed to adhere to poly-Llysine coated glass cover slips in 6-well plates for 30 min in a 37oC incubator, after
which 0.5 mL of culture medium was added to the wells and the cells maintained in a
humidified, 37oC environment of 5% CO2. Culture medium was changed 24 hr after
plating, and cells were used 48 hr after isolation.
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2. Intracellular Calcium Measurements
Intracellular Ca2+ transients were analyzed using established protocols as
previously described (Liu et al., 2001; Jorgensen et al., 2002). In each experiment,
cytosolic Ca2+ was measured simultaneously in 5-12 chromaffin cells loaded with the
fluorescent dye fura-2 using a dual-excitation spectrofluorometric system (Zeiss
AttoFluor Ratio Vision Workstation, Atto Instruments, Inc.; Rockville, MD).

Before

experimental analysis, the cells were rinsed 3X with HBSS and loaded with 5 µM fura2AM plus 0.1% Pluronic F-127 for 45 min at 37oC. After this time, the cells were rinsed
again with HBSS and allowed to recover for at least 15 min.

The cover slip was

mounted in a closed perfusion chamber (Warner Instrument Corp.; Hamden, CT),
placed on the stage of a Zeiss Axiovert inverted microscope fitted with a 40X
fluorescence oil immersion objective, and constantly perfused by gravity-feed with
ambient temperature HBSS at 1-3 mL/min.
For these experiments, non-stimulated (basal) fluorescence was measured for
approximately 30 sec, an agonist was added by a rapid change-out of the bathing
medium, and was removed after 15 sec by a second bath change-out. There was a 10
min recovery period before each re-stimulation. Fluorescence was determined using
excitation wavelengths of 340 nm and 380 nm and an emission wavelength of 510 nm.
Ratiometric data were collected and converted to cytosolic Ca2+ ([Ca2+]i) estimates
based on a curve generated using a two-point calibration method and the following
equation (Grynkiewicz et al., 1995):
[Ca2+]i = Kd [(R – R(min) / R(max) – R)] X [Den(min)/Den(max)]
where R = measured ratio; Kd = dissociation constant for the dye; R(min) = ratio
for the low standard (Ca2+ -free solution); R(max) = ratio for high standard (10
mM Ca2+ solution); Den(min) = denominator intensity for the low standard; Den
(max) = denominator intensity for the high standard.
B. NCI-H295R cells
1. Cell Culture
An aliquot of the adrenal cortical cell line NCI-H295R was obtained from
American Type Culture Collection (ATCC; Manasssas, VA) and the cells were grown
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according to the product information sheet supplied. Cells were maintained in complete
growth medium containing a 1:1 mixture of Dulbecco’s Modified Eagle’s Medium and
Ham’s F12 medium + L-glutamine (2.5 mM), HEPES (15 mM), sodium pyruvate (0.5
mM), and sodium bicarbonate (1.2 g/L) , supplemented with 2.5% Nu-Serum (BD
Biosciences) and the additives insulin (6.25 µg/mL), transferrin (6.25 µg/mL), selenium
(6.25 µg/mL), bovine serum albumin (1.25 mg/mL), and linoleic acid (5.35 µg/mL) in a
humidified, 37oC environment with 5% CO2. Cells were subcultured weekly at a ratio of
1:4 using a solution of 0.25% Trypsin-EDTA.
2. cAMP Accumulation
Incubations were conducted on H295R cells in 24-well plates (200,000
cells/well). The well plates were placed in a 37oC water bath and the culture medium
removed and replaced with warmed pre-incubation medium (0.25 mL) consisting of
Eagle’s Balanced Salt Solution (EBSS, pH 7.4) supplemented with the cAMP
phosphodiesterase inhibitor Ro20-1724 (25 µM; Calbiochem; La Jolla, CA). After 10
min of pre-incubation, warmed incubation medium (0.25 mL) containing either vehicle or
agonist in pre-incubation medium was added to the wells. The medium was removed
after 10 minutes of incubation and 0.25 mL of HCl (0.01 M) was added to the wells. For
protein analysis, 5% SDS (0.3 mL) was added in place of HCl to at least 4 wells from
every experimental plate. The plates were stored at -80oC for later analysis by enzyme
immunoassay (EIA).

Analytical Techniques
A. Plasma Epinephrine ELISA
Plasma concentration of free EPI was determined by a non-competitive,
monoamine specific ELISA kit (KMI-IBL; Hamburg, Germany). EPI was extracted from
kit standards, kit controls and plasma samples (0.25 mL) and was chemically converted
to biotin derivatives. Basal samples were diluted 1:2, 30 min and 60 min samples were
diluted 1:5 with HCl provided in the kit. Standards, controls and diluted samples (0.05
mL) were added in duplicate to the antigen-coated wells of a 96-well plate and the
extracted EPI was enzymatically methylated and bound to antigens for N-
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acylmetanephrine. After a wash step, the wells were incubated in a solution of antibiotin antibodies conjugated with alkaline phosphatase for 90 min, followed by second
wash step.

The sandwich complex fixed to the wells was visualized with a signal

amplification system, which utilizes NADPH as the substrate for alkaline phosphatase
and allows the conversion of p-iodonitrotetrazolium (colorless) to formazan (hot
pink/red). The reaction was stopped after 15 min by the addition of H2PO4 and the
developed color intensity was measured at 490 nm (reference wavelength 600-650 nm)
within 1 hr using a 96-well plate reader (µQuant, Bio-Tek Inc; Winooski, VT).

All

incubation steps required constant shaking (400-600 rpm) and were performed at room
temperature. It was essential for assay precision that the washes utilize an auto strip
washer (ELx50, Bio-Tek). Concentrations of samples were determined with the aid of
KC-4 software (Bio-Tek), which interpolated the mean measured absorbancies against
the standard curve (Figure 2.7) on each plate. All comparisons were intra assay and
the coefficient of variation (c.v.) was 9.8 ±1%.
B. Measurement of Plasma Estradiol Concentration
1. Estradiol Extraction
Estradiol was extracted from rat plasma samples prior to assay by diethyl ether
extraction. Samples (0.2 mL) and diethyl ether (3 mL) were added to 16X125 mm
vortex tubes in duplicate and tightly capped. Samples were vigorously vortexed for 5
min and the aqueous layer was frozen in an ethanol/dry ice bath.

The ether

supernatant was decanted into 12X75 mm tubes, the ether evaporated and the tubes
completely dried. This process was accelerated by heating the samples to 40oC and
placing under a vacuum. The tubes were rinsed with ether and dried three additional
times to ensure that the extracted estradiol accumulated at the bottom of the tube. A
set of clean 12X75 mm tubes used as standard and control assay tubes were washed
with ether and dried at the same time as the samples.
2. Estradiol RadioImmunoAssay
Plasma concentration of free estradiol was determined by an estradiol-specific
RIA kit (DSL; Webster, TX).

After the final wash down and evaporation step of the
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extraction, the samples were reconstituted in 0.2 mL of the zero standard from the kit
and the appropriate volumes of kit-provided standards or controls were added to the
ether washed, empty tubes.

Tubes (except the total count and non-specific binding)

were incubated with estradiol-antiserum (4 hr, 4oC), and I-125 labeled estradiol was
added to all assay tubes and the tubes incubated again at 4oC for 20-24 hr. Tubes
(except total count) were then incubated with precipitating reagent for 20 min at room
temperature, centrifuged for 15 min at 1500 X g, decanted, and the iodinated estradiol
contained in all tubes was measured for 1 min by gamma counter. The percent ratio of
the bound fraction of labeled estradiol in each sample (B) to that in the absence of
unlabelled estradiol (Bmax) was calculated and interpolated against the standard curve
to determine sample concentrations (Figure 2.8). Control samples were assayed both
in extracted and non-extracted form.
C. cAMP EIA
Accumulated cAMP in the H295R cells was determined by a competitive EIA kit
(Cayman Chemical; Ann Arbor, MI). First, the experimental well plates were thawed
and scraped to ensure total cell lysis and release of cAMP into the HCl. The samples
were then transferred to 1.5 mL microcentrifuge tubes and centrifuged at 1,000 X g for
10 min. Standards, controls, and samples were acetylated in 12X75 mm tubes and
0.05 mL of each was added in duplicate to anti-rabbit IgG coated wells of a 96-well
plate. cAMP acetylcholinesterase (Tracer) and cAMP antiserum were added to the
appropriate wells and the plate was incubated 18-24 hrs at 4oC.

The wells were

washed using a plate washer (ELx50, Bio-Tek) and incubated in the dark with shaking
(400-600 rpm) for 2 hrs at 25oC with the acetylchotinesterase (AChE) substrate
(designated as Ellman’s reagent). The intensity of the color (yellow) that developed was
measured at 420 nM and was inversely proportional to the amount of free cAMP
present. The percent ratio of the AChE- labeled cAMP in the sample bound to the
antibody (B) to the maximum capacity of the antibody for AChE-labeled cAMP in the
absence of unlabelled cAMP (Bmax) was calculated and interpolated against the
standard curve (Figure 2.9) to determine sample concentrations.
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D. Adrenal Medullary Gene Expression
1. RNA isolation
Adrenal medullary tissue was dissected from the adrenal glands of rats in the
three treatment paradigms and was stored in RNAlater (Ambion; Houston, TX) at -20oC
P

P

prior to RNA isolation. Total RNA was extracted using an RNeasy Mini Kit (Quiagen;
Valencia, CA).

Tissue was homogenized in a guanidine isothiocyanate-containing

buffer with a Duall tissue grinder (Fisher Scientific; Pittsburg, PA). The samples were
centrifuged at 12,000 X g for 3 min and the supernatant was transferred to 1.5 mL
microcentrifuge tubes. One volume of ethanol (70%) was added to all samples and the
solution applied to an RNeasy mini column containing a silica-gel membrane.

The

columns were centrifuged for 15 sec at 8,000 X g and the flow-through discarded. After
an on-column DNase digestion and two high-salt washes, the total RNA was eluted
from the column membrane with 0.03 mL of nanopure water and quantified
spectrometrically at 260 nM.
2. Reverse Transcription
Single- stranded cDNA was synthesized from 1 µg of RNA using a Thermoscript
RT kit (Invitrogen Life Technologies; Carlsbad, CA) and a protocol previously described
(Carrithers et al., 2000). The samples were incubated for 5 min at 65oC with random
P

P

hexamers (final concentration of 5 µM) and dNTPs (final concentration of 1 mM) and
immediately placed on ice. RT components were added as a master mix containing (in
final concentrations): 1X cDNA synthesis buffer (25 mM Tris acetate (pH 8.4), 75 mM
potassium acetate, 8mM magnesium acetate); 0.75 U Thermoscript reverse
transcriptase; 5 mM DTT; 2U RNase OUT. Samples were incubated at 25oC for 10 min,
P

P

55oC for 60 min, and 85oC for 5 min. RNase H (1 µL) was added to each reaction and
P

P

P

P

incubated at 37oC for 20 min to degrade existing RNA molecules. The cDNA synthesis
P

P

reactions were stored at -20oC or used immediately for polymerase chain reaction.
P

P

3. Polymerase chain reaction (PCR)
An initial PCR reaction determined the amount of β-actin generated by 1 µL of
each RT reaction at 26 cycles. Subsequent PCR reactions were prepared with volumes
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of RT reaction which were estimated (by CDD camera) to generate equal amounts of βactin. The 50 µL PCR reaction mixture consisted of (in final concentrations): cDNA
template (~ 5% of RT reaction); 20 mM Tris-HCl (pH 8.0); 50 mM KCl; 0.2 mM dNTPs;
0.4 µM primers; 2 mM MgCl2 and 2.5 U of Platinum Taq Polymerase (Invitrogen Life
B

B

Technologies). PCR reactions utilized a Perkin Elmer GeneAmp PCR system 2400
(Applied Biosystems; Foster City, CA).

Control reactions were performed in the

absence of cDNA. Samples (20% of reaction volume) were size fractionated by 3%
agarose gel electrophoresis. Ethidium bromide stained DNA bands were visualized by
a UV Foto/analyst image analysis system equipped with a convertible dual
transilluminator (Fotodyne; Hartland, WI). The signal intensity of each PCR product
was determined by an electronic imaging and analysis system with a CCD video
camera (Fotodyne) and analyzed by UN-SCAN-IT software (Silk Scientific Inc; Orem,
UT). The primer sequences and cycle protocols for tyrosine hydroxylase (TH; Murru et
al., 1997), phenylethanolamine N-methyltransferase (PNMT; Morita et al., 2001),
estrogen receptor α (ERα; Kuiper et al., 1997), estrogen receptor β (ERβ; Byers et al.,
1997), and β-actin (Carrithers et al., 2000) have been previously published and are
listed in Table 2.2.
E. Adrenal Medullary Protein Expression
1. Protein Isolation
Adrenal

medullary

tissue

was

dissected

from

the

adrenal

glands

of

ovariectomized, vehicle and estradiol-treated rats and stored at -80oC prior to protein
P

isolation.

P

Samples were homogenized in a lysis buffer (pH 6.4) consisting of 25mM

MES, 0.15mM NaCl, 1% TritonX-100, and 60mM n-octyl-β-D-glucopyranoside, stored
on ice for 15 min, centrifuged (14,000g) at 4oC for 10 min. The supernate was collected
P

P

and stored at -20oC. Prior to use, 5X protein sample buffer (pH 6.8) consisting of 0.31M
P

P

P

P

Tris, 2.5% (w/v) SDS, 50% glycerol and 0.125% bromophenol blue was added to a final
concentration of 1X. All samples were heated to 95oC immediately prior to loading.
P
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P

2. Immunoblot
Proteins were separated on a 12.5% polyacrylamide gel at 50mA (constant
current) and subsequently transferred to PVDF membrane (0.45µM; Sigma) at 50V
(constant voltage) for 2 hours. Membranes were blocked with blotting buffer consisting
of TBS plus 0.5% Tween 20 and 5% dry milk for 1 hr at 22 oC. Primary antibodies for
P

P

ERα (Upstate Biotechnology; Lake Placid, NY), TH (BD Transduction Labs; San Jose,
CA), and PNMT (Dia Sorin Inc; Stillwater, MN) were diluted in blotting buffer and
incubated with blocked membranes for 1-24 hrs at 22oC. Membranes were washed four
P

P

times for 5 min in a buffer containing TBS plus 0.5% Tween 20 and 0.2% dry milk.
Horseradish peroxidase conjugated IgGs directed against the appropriate host IgG were
diluted and incubated with membranes for up to 1 hr. Membranes were washed four
times and visualized using chemiluminescence. The relative signal intensities were
determined densitometrically. Equality of protein loading was determined qualitatively
by Ponceau S staining of membranes.
F. Protein Concentration Analysis
Protein concentrations of H295R cells and adrenal medullary tissue samples
were determined by the colorimetric DC Protein Assay (Bio Rad; Hercules, CA). This
technique is similar to Lowry protein analysis. Samples were thawed, triturated and
0.05 mL was added in duplicate to 12 X 75 mm tubes as were bovine serum albumin
standards (in 5% SDS, [0, 2.5, 5, 10, 25, and 50 mg/mL]). A working solution of 0.02
mL Reagent S per 1 mL Reagent A (alkaline copper tartrate solution) was made and 0.2
mL added to all tubes along with 1.5 mL of Reagent B (dilute Folin solution). All tubes
were vortexed vigorously and the color (blue) developed for 15 min at 25oC.
P

P

Absorbance was measured at 550 nM.
G. Statistical Analysis
Results are expressed as Mean ± SEM. Statistical significance was determined
using a t-test, paired t-test or ANOVA as appropriate. Post-hoc analysis to compare
multiple treatment groups utilized the Student-Newman-Keuls test. Significance level
was set at P<0.05.
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Uterine Weight (mg/mm)

∆ Body Weight (g)

2 Weeks After Surgery

2 Weeks After Surgery

SHAM

123 ± 9.5

-1.5 ± 5.6

OVEX

50 ± 8.6*

+39 ± 1.5*

OVEX +E2

110 ± 7.4**

-8 ± 0.9**
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Table 2.1
Effect of Ovariectomy and Estradiol-Replacement in Ovariectomized Rats on Uterine
Weight and Total Body Weight

Uterine weight and changes in body weight 14 days after sham-surgery (SHAM),
ovariectomy (OVEX), or ovariectomy + E2 replacement (OVEX +E2). Values are Mean
± SEM of data from 5 separate experiments. * P< 0.01 compared to the SHAM group.
** P< 0.05 compared to the OVEX group.
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Figure 2.1
Plasma Estradiol Concentrations

Plasma estradiol concentrations were measured 14 days after ovariectomy (OVEX), or
ovariectomy + E2 replacement (OVEX +E2).

Plasma estradiol concentration was

measured 12-16 days after surgery in the sham-operated controls (SHAM) on the proestrous day of the estrous cycle. Columns represent Mean ± SEM of data from 5
separate experiments. * P< 0.01 compared to the SHAM group. ** P< 0.01 compared
to the OVEX group.
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Figure 2.2
Summary of the Insulin-Induced Hypoglycemia Paradigm

OVEX: ovariectomy; E2: 17β-estradiol
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Figure 2.3
Effects of the Blood-Sampling Protocol on
Epinephrine Concentrations

Plasma glucose and epinephrine (EPI) concentrations in sham-operated rats during the
hypoglycemic-stress paradigm blood sampling protocol in the absence of insulin.
Vehicle (saline; 100 µL) was administered intravenously as a bolus at time 0. Arterial
blood samples (0.6 mL) were taken immediately prior to and 30 and 60 minutes after
the vehicle. Upper Panel: Plasma glucose concentrations. Lower Panel: Plasma EPI
concentrations. Circles (upper panel) and columns (lower panel) represent Mean ± SEM
of data from 4-5 separate experiments.
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Figure 2.4
Effect of 0.25 U/kg and 1.0 U/kg Insulin Bolus on Plasma Glucose and Epinephrine
Concentrations

Experiments were conducted 14 days after sham-surgery.

Insulin (0.25 U/kg or 1.0

U/kg) was administered intravenously as a bolus at time 0. Arterial blood samples (0.6
mL) were taken immediately prior to and 30 and 60 minutes after the insulin. Upper
Panel:

Plasma glucose concentrations. Lower Panel:

Plasma epinephrine (EPI)

concentrations. Circles (upper panel) and columns (lower panel) represent Mean ± SEM
of data from 6-8 separate experiments. * P< 0.01 compared to the 0.25 U/kg treated
group.
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Figure 2.5
Typical Renal Sympathetic Nerve Recording

Upper Panel: Raw nerve activity over 60 milliseconds. Middle Panel: Rectified nerve
activity over 60 milliseconds. Lower Panel: Rectified nerve activity integrated over 0.01
second integrals for 10 seconds.

32

33

Figure 2.6
Protocol for Measurement of Plasma Epinephrine Clearance

OVEX: ovariectomy; E2: 17β-estradiol; EPI: epinephrine
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Figure 2.7
Representative Standard Curve Used for the
Determination of Epinephrine Concentration by ELISA

Standard curve used for the determination of epinephrine (EPI) concentrations in rat
plasma.

Up-pointing triangle represents the actual measured concentration (5.6

pg/mL) of a kit-provided low-concentration control (Control 1) with a range of 3.1-6.5
pg/mL.

Down-pointing triangle represents the actual measured concentration (19.6

pg/mL) of a kit-provided high-concentration control (Control 2) with a range of 13.4-26.1
pg/mL.
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Figure 2.8
Representative Standard Curve Used for Determination of Estradiol Concentrations by
RIA

Standard curve used for the determination of estradiol concentrations in rat plasma.
Up-pointing triangle represents the actual measured concentration (12 pg/mL) of an
extracted, kit-provided low-concentration control (Control 1) with a range of 10 ± 3
pg/mL.

Down-pointing triangle represents the actual measured, concentration
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Representative Standard Curve Used for the
Determination of cAMP Levels by EIA
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Gene

Primer Sequence (5’ to 3’)

TH

(+) ACATTTGAACTTAAAATTCAC
(-) CGGGTGGTCCAGGTCCAGAT

PNMT
ERα
ERβ
βactin

base pairs

263

(+) CAGACTTCTTGGAGGTCAACCG
(-) TTATTAGGTGCCACTTCGGGTG

610

(+) AATTCTGACAATCGACGCCAG
(-) GTGCTTCAACATTCTCCCTCCTC

344

(+) AAAGCCAAGAGAAACGGTGGGC
(-) GCCAATCATGTGCACCAGTTCC

203

(+)TGGTGGGAATGGGTCAGAAGGACTC
(-) CATGGCTGGGGTGTTGAAGGTCTCA

265
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Cycle

29
30
36
38
26

#

Cycle Protocol
Temp
Time

94oC
55oC
72oC
94oC
55oC
72oC
95oC
55oC
72oC
94oC
62oC
72oC
94oC
63oC
72oC
P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

0.5
0.5
1.0
0.5
0.5
1.0
1.0
1.0
2.0
0.5
1.0
1.5
1.0
1.0
1.0

min
min
min
min
min
min
min
min
min
min
min
min
min
min
min

Table 2.2
PCR Primer Sequences and Protocols
TH: tyrosine hydroxylase; PNMT: phenylethanolamine N-methyltransferase; ERα:
estrogen receptor α; ERβ: estrogen receptor β
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Chapter 3: Results
A. Estrogen Receptor Expression
In order for estradiol to affect adrenal medullary function via conventional steroid
pathways, receptors for the steroid must be present in the tissue.
RT-PCR analysis identified mRNA for both estrogen receptor α (ERα) and β (ERβ) in
the adrenal medullary tissue of sham-operated controls (Figure 3.1; upper panel). ERβ
expression was more evident than ERα expression in the sham group. The expression
of both receptors in medulla was markedly lower than in uterine (ERα) and the ovarian
(ERβ) tissue. While the expression of ERα appeared to be increased by ovariectomy,
densometric comparisons (Figure 3.1; lower panel) were not significant and estradiol
replacement did not affect ERα expression in ovariectomized (OVEX) rats. ERβ mRNA
levels did not differ between ovariectomized and sham groups or estradiol-replaced and
vehicle-treated OVEX groups. A limited number of immunoblot samples confirmed that
ERα did translate to receptor protein in the medulla, but at a reduced level compared to
expression in the uterus (Figure 3.2; upper panel). Expression levels did not differ
between vehicle-treated and estradiol-replaced OVEX groups (Figure 3.2; lower panel).
Attempts to measure ERβ protein expression proved unsuccessful.

B. Effects of Physiological Concentrations of Estrogen
1. Effects of the Loss of Ovarian Steroids
Experiment 1 compared the effects of insulin-induced hypoglycemia on plasma
epinephrine concentration in 14-day OVEX and sham-operated rats. Pre-insulin plasma
glucose concentration did not differ between the groups, and the glucose lowering
effects of 0.25 U/kg insulin were identical in both groups at 30 (∆ -67 ± 2.3%) and 60 (∆
-36 ± 2.3%) minutes post-treatment (Figure 3.3; upper panel). Pre-insulin plasma
epinephrine concentrations also did not differ between groups (150 ± 25 vs. 150 ± 26
pg/mL). However, 30 min of hypoglycemia increased plasma epinephrine concentration
to a significantly greater extent (∆ +112%; P< 0.01) in the OVEX group compared to the
sham-operated controls (Figure 3.3; lower panel). At 60 min post-insulin, plasma
epinephrine concentrations were lower than at 30 min and did not differ between the
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groups. Heart rate did not differ between the groups at any time point (Figure 3.4; upper
panel). Mean arterial blood pressure (MAP) was significantly decreased (P<0.001) to
exactly the same extent after 30 min of hypoglycemia in the sham and OVEX groups (∆
-20 ± 4.0% and -21 ± 2.3% respectively) and remained depressed after 60 min (Figure
3.4; lower panel).

2. Effects of Estradiol Replacement
In order to assess the effects of estradiol per se in this response, experiment 2
compared the effects of insulin-induced hypoglycemia on plasma epinephrine in 14-day
OVEX and estradiol-replaced OVEX rats. For these experiments, one SILASTIC
capsule containing either 17β-estradiol (E2) or sesame oil (vehicle) was implanted at
the time of ovariectomy.

As described in the materials and methods section, this

replacement paradigm produced plasma E2 concentrations that were almost identical to
those seen in intact, late proestrous phase, female rats (20.0 ± 2.4 and 22.0 ± 2.5 pg/ml
respectively). Plasma E2 concentration in the OVEX animals (8.5 ± 0.6 pg/mL) was
significantly lower than in both the intact and the E2-replaced OVEX rats (P<0.01).
Pre-insulin plasma glucose concentrations did not differ between vehicle-treated
and E2-treated OVEX rats (95 ± 3.4 and 103 ± 3.5, respectively) and were decreased to
the same extent 30 min after insulin (∆ -64 ± 2.6%; Figure 3.5; upper panel). Pre-insulin
plasma epinephrine concentrations also did not differ between groups (133 ± 29 vs. 152
± 30 pg/mL). However, at 30 min post-insulin, the hypoglycemia-induced increase in
plasma epinephrine concentration was significantly lower (∆ -56%; P< 0.001) in the
OVEX +E2 group compared to the vehicle-treated OVEX (Figure 3.5; lower panel).
Comparing across experiments, the increase in plasma epinephrine in the E2-replaced
group was, in fact similar to that elicited in the SHAM group of experiment 1 (∆ 416 ± 75
vs. 550 ± 73 pg/mL). At 60 min post-insulin, plasma epinephrine concentrations again
did not differ between groups despite the fact that plasma glucose was significantly
lower in the OVEX compared to the OVEX +E2 group at this time point (61 ± 4.8 vs. 88
± 9.0 mg/dL respectively; P<0.05). Heart rate and MAP during hypoglycemia were
similar to those seen in experiment 1. Heart rate remained constant in both groups and
was not different between groups at any time point (Figure 3.6; upper panel). MAP

44

significantly decreased after 30 min of hypoglycemia in both groups (∆ -21 ± 2.5% and
-17 ± 2.4%, OVEX and OVEX +E2 respectively; P<0.001) and remained depressed
after 60 min (Figure 3.6; lower panel), but was not different between groups at any time
point.
To this point, experiments demonstrate that physiological levels of E2 can
suppress

stress

(hypoglycemia)-induced

increases

in

plasma

epinephrine.

Theoretically, this could result from a steroid-mediated decrease in epinephrine
secretion from the adrenal medulla and/or increase in the plasma clearance of
epinephrine. Measurement of epinephrine levels in blood collected directly from the
adrenal vein was utilized as an index of epinephrine secretion.

Given the highly

invasive nature of these studies, blood sampling was restricted to one 6 min period
beginning 24 min post insulin, during a time of lowest plasma glucose. Consistent with
the plasma data, epinephrine secretion during this time period was significantly lower in
the OVEX +E2 group compared to the OVEX (∆ -44%; P<0.005; Figure 3.7). This E2mediated decrease in secretion could be due to several factors, including decreased
epinephrine synthesis in the adrenal medulla, suppressed intracellular signaling for
secretion in the chromaffin cells of the medulla, and/or decreased neural input to the
medulla.
Our data do not support the concept that E2 affects epinephrine biosynthesis.
Using semi-quantitative RT-PCR,

mRNA expression levels for tyrosine hydroxylase

(TH), the rate limiting enzyme in the catecholamine biosynthetic cascade, and for
phenylethanolamine N-methyltransferase (PNMT), the enzyme necessary for the
conversion of nor-epinephrine to epinephrine, did not differ between OVEX and sham or
E2-replaced and vehicle-treated OVEX groups (Figure 3.8).

Similarly, protein

expression of these enzymes measured by immunoblot also was not different in OVEX
+E2 compared to OVEX rats (Figure 3.9).
Isolated adrenal medullary chromaffin cells maintained in primary culture were
used to assess the effects of E2 on agonist-induced increases in intracellular Ca2+,
P

P

which is the primary stimulus for epinephrine secretion. Exposure to 10 nM E2 for 48 hr
had no significant effect on Ca2+ transients elicited by either 50 µM nicotine (NIC) or by
P

P

60 mM KCl when compared to vehicle-treated control cells (Figure 3.10). In contrast,
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short-term treatment (3 min) with relatively high concentrations of E2 dose-dependently
suppressed agonist-induced Ca2+ transients in chromaffin cells.
P

P

At 5 µM E2, NIC-

induced Ca2+ transients were significantly suppressed by 33 ± 2.0% (P< 0.001; Figure
P

P

3.11; upper panel); transients were almost completely abolished with exposure to 50 µM
E2 (∆ -88 ± 4.2%; P<0.001). The suppressive effects of E2 were rapidly reversible. For
example, exposure to 10 µM E2 inhibited NIC-induced responses by 48 ± 4.6% (P<
0.001). Following removal of E2, the amplitude of the Ca2+ transient returned to 92 ±
P

P

4.6% of control within 10 min (Figure 3.11; lower panel).

Increasing the time of

exposure to E2 to 10 and 20 minutes had no additional inhibitory effect (Figure 3.12;
upper panel). Ca2+ transients stimulated by KCl were inhibited 50% (P<0.001) by 3 min
P

P

treatment with 50 µM E2 (Figure 3.12; lower panel).
The effects of these two in vitro treatment paradigms were diametrically opposite
in adrenal cortical cells compared to chromaffin cells.

Pituitary adenylate cyclase-

activating polypeptide-27 (PACAP-27; 100 nM)- induced increases in intracellular cAMP
accumulation were significantly decreased in cells from a human adrenal cortical cell
line (H295R) exposed to 10 nM E2 for 48 hr compared to vehicle-treated controls (∆ 33%; P<0.05; Figure 3.13).

However, acute exposure to a supra-physiological

concentration of E2 (50 µM) did not affect agonist-induced cAMP accumulation in this
cell line (Figure 3.14).
Subsequent experiments assessed the effects of E2 on renal sympathetic nerve
activity (RSNA) as an index of neural input to the adrenal medulla. As in previous
experiments, insulin reduced plasma glucose concentrations to the same extent in both
groups.

Hypoglycemia elicited a maximal increase in RSNA above baseline

approximately 25 min after insulin in both groups and was significantly greater in the
OVEX +E2 compared to the OVEX group (49 ± 6.0% vs 16 ± 1.8%; P< 0.01). Activity
returned toward baseline after peak, but remained significantly augmented above
baseline for the duration of the experiment in the OVEX +E2 group. However, in the
OVEX group, RSNA had returned to baseline after 45 min of hypoglycemia, and was
thereafter significantly decreased below baseline levels (Figure 3.15).
To evaluate the effects of estradiol on epinephrine clearance, plasma
epinephrine concentrations were compared in OVEX and OVEX +E2 rats before and
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during infusion of three successively increasing doses of exogenous epinephrine. Preinfusion plasma epinephrine concentrations did not differ between the groups (108 ± 19
vs. 92 ± 9 pg/mL). As anticipated, plasma epinephrine concentrations increased as the
epinephrine infusion rate was increased in both groups. These increases in plasma
epinephrine levels were significantly lower in the E2-replaced OVEX animals (∆ -39% at
30 min, ∆ -34% at 60 min, and ∆ -42% at 90 min; P<0.05; Figure 3.16), suggesting that
the rate of epinephrine clearance is greater in this group compared to the OVEX group.

C. Effects of Supra-Physiological Concentrations of Estradiol
Consistent with other reports, our work has demonstrated that acute exposure to
high concentrations of estradiol can suppress agonist-induced Ca2+ transients in the
P

P

chromaffin cell. Based on previous work from our laboratory (Wagner et al., 1999;
Jorgensen et al., 2002), we would anticipate that this reduction in Ca2+ signaling would
P

P

result in decreased epinephrine secretion. Subsequently, experiments were designed
to determine whether acute increases in circulating E2 can affect hypoglycemia-induced
increases in plasma epinephrine. The following modifications were applied to the basic
hypoglycemia protocol for these experiments: only ovariectomized rats were used and
a bolus dose of E2 (150 µg/kg) or vehicle (10% EtOH) was intravenously infused over 2
min 30 min prior to the insulin bolus. To maintain a high plasma concentration of free
E2, rats were infused with either E2 or vehicle at a rate of 75 µg/kg/hr for the remainder
of the experiment.
Plasma glucose concentrations measured immediately prior to and 30 min after
E2 or vehicle administration did not differ and the glucose lowering effects of insulin
were identical in both groups at 30 and 60 min post-insulin (∆ -66 ± 1.6% and ∆ -35 ±
3.1%; Figure 3.17; upper panel). Plasma epinephrine concentrations also did not differ
prior to (82 ± 29.9 vs. 105 ± 16.5 pg/mL) or 30 min after (154 ± 23.0 vs. 203 ± 32.3
pg/mL) E2 or vehicle administration. E2 treatment significantly suppressed the rise in
plasma epinephrine concentration after 30 min of hypoglycemia (∆ -34%; P< 0.05), and
tended to suppress the rise at 60 min post-insulin (Figure 3.17; lower panel). In contrast
to experiment 1 and 2, heart rate did increase after 30 min in the E2-infused group, and
after 60 min in the vehicle-infused group, but these increases did not reach significance
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(P=0.06 and P=0.07 respectively; Figure 3.18; upper panel).

Also in contrast to

experiments 1 and 2, MAP remained stable for the duration of the 60 min hypoglycemic
test in both groups. Neither heart rate nor MAP was different between the groups at
any time point (Figure 3.18; lower panel).

D. Effects of Gender
Since the data to this point have established that both physiological and supraphysiological levels of E2 can modulate stress-induced epinephrine responses, a final
series

of

experiments

compared

hypoglycemia-induced

increases

in

plasma

epinephrine concentration in age-matched (14 week-old) male and female rats. Plasma
glucose concentration did not differ between the groups prior to insulin treatment (92 ±
1.2 and 98 ± 3.3 mg/dL; male and female respectively). The glucose lowering effects of
insulin were identical in both groups (∆ -62 ± 2.2%) after 30 min of hypoglycemia.
Plasma glucose levels were returned toward baseline after 60 min in both groups, but
had returned to a greater degree in the female rats (73 ± 3.7 vs. 56 ± 3.7 mg/dL; P<0.01
p) (Figure 3.19; upper panel). Pre-insulin plasma epinephrine concentrations were
significantly higher in the female group compared to the male group (113 ± 6 vs. 79 ± 11
pg/mL; P<0.05). Hypoglycemia-induced increases in plasma epinephrine concentration
were greater in the female group after 30 min (∆ + 308%; P<0.05) and did not differ
after 60 min (Figure 3.19; lower panel), but heart rate was significantly increased above
baseline after 30 min of hypoglycemia in the female group (∆ +10%; P<0.05). Heart
rate did not differ between the groups at any time point (Figure 3.20; upper panel).
MAP significantly decreased over time in both groups, but also did not differ between
groups (Figure 3.20; lower panel).
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Figure 3.1
Estrogen Receptor Gene Expression in the Adrenal Medulla

Semi-quantitative RT-PCR analysis of adrenal medullary mRNA levels for estrogen
receptor α (ERα) and estrogen receptor β (ERβ). Tissue was collected 14 days after
ovariectomy (OVEX), SHAM- surgery, ovariectomy + estradiol replacement (OVEX +
E2) or + vehicle treatment (OVEX + VEH).

Upper Panel:

This ethidium bromide-

stained agarose gel illustrates each PCR product (n = 3 per group). The size of each
product is listed in the left column. Uterine (UT) tissue was used as a control for ERα
expression, ovarian (OV) tissue was used as a control for ERβ expression; β-actin was
used as an internal control for each reaction.

Lower Panel: Densitometric analysis of

the relative signal intensities. Columns (lower panel) represent Mean ± SEM of data
from the 3 individual experiments in the upper panel.
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Figure 3.2
Estrogen Receptor α Protein Expression in the Adrenal Medulla

Immunoblot analysis of adrenal medullary protein levels for estrogen receptor α (ERα).
Tissue was collected 14 days after ovariectomy + vehicle (OVEX) or estradiol
replacement (OVEX + E2). Upper Panel: 100 µg of adrenal medullary and 20 µg of
uterine (UT) protein were separated by SDS-PAGE (n = 3 per group) and subjected to
immunoblot analysis with rabbit anti ERα in a dilution of 1:2000 overnight. The size of
the product is listed in the left column. Lower Panel: Densitometric analysis of the
relative signal intensities. Columns (lower panel) represent Mean ± SEM of data from
the 3 individual experiments in the upper panel.
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Figure 3.3
Effect of Ovariectomy on Hypoglycemia-Induced Increases in Plasma Epinephrine
Concentration

Experiments were conducted 14 days after ovariectomy (OVEX) or sham-surgery
(SHAM).

Insulin (0.25 U/kg) was administered intravenously as a bolus at time 0.

Arterial blood samples (0.6 mL) were taken immediately prior to and 30 and 60 minutes
after the insulin. Upper Panel: Effect of insulin on plasma glucose concentrations. Lower
Panel: Effect of hypoglycemia on plasma epinephrine (EPI) concentrations.

Circles

(upper panel) and columns (lower panel) represent Mean ± SEM of data from 7-8
separate experiments. * P < 0.01 compared to SHAM group.
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Figure 3.4
Effect of Ovariectomy on Hypoglycemia-Induced Changes in Heart Rate and Mean
Arterial Blood Pressure

Upper Panel: Effect of hypoglycemia on heart rate.

Lower Panel: Effect of

hypoglycemia on mean arterial blood pressure (MAP). Experiments were conducted 14
days after ovariectomy (OVEX) or sham-surgery (SHAM). Insulin was administered
intravenously as a bolus at time 0. Circles represent Mean ± SEM of data from 7-8
separate experiments.
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Figure 3.5
Effect of Estradiol-Replacement in Ovariectomized Rats on Hypoglycemia-Induced
Increases in Plasma Epinephrine Concentration

Experiments were conducted 14 days after ovariectomy (OVEX); estradiol (E2)- or
vehicle (sesame oil)-containing SILASTIC capsules were implanted at the time of
surgery. Arterial blood samples (0.6 mL) were taken immediately prior to and 30 and 60
minutes after the insulin. Upper Panel: Effect of insulin on plasma glucose
concentrations. Lower Panel: Effect of hypoglycemia on plasma EPI concentrations.
Circles (upper panel) and columns (lower panel) represent Mean ± SEM of data from 78 separate experiments. * P<0.001 compared to OVEX group.
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Figure 3.6
Effect of Estradiol-Replacement in Ovariectomized Rats on Hypoglycemia-Induced
Changes in Heart Rate and Mean Arterial Blood Pressure

Upper Panel: Effect of hypoglycemia on heart rate. Lower Panel: Effect of hypoglycemia
on mean arterial blood pressure (MAP). Experiments were conducted 14 days after
ovariectomy (OVEX); estradiol (E2)- or vehicle (sesame oil)-containing SILASTIC
capsules were implanted at the time of surgery. Circles represent Mean ± SEM of data
from 7-8 separate experiments.
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Figure 3.7
Effect of Estradiol-Replacement in Ovariectomized Rats on Hypoglycemia-Induced
Increases in Adrenal Epinephrine Output
Experiments were conducted 14 days after ovariectomy (OVEX); estradiol (E2)- or
vehicle (sesame oil)-containing SILASTIC capsules were implanted at the time of
surgery. The left renal vein was isolated so that blood flow from the adrenal vein branch
could be sampled. Epinephrine (EPI) concentrations were measured in blood samples
collected during one 6 min period starting 24 min after the insulin. Columns represent
Mean ± SEM of data from 4-5 separate experiments. * P<0.005 compared to OVEX
group.
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Figure 3.8
Effects of Ovariectomy and Estradiol-Replacement in Ovariectomized Rats on Adrenal
Medullary Gene Expression of Catecholamine Biosynthetic Enzymes

Adrenal

medullary

tyrosine

hydroxylase

(TH)

and

phenylethanolamine

N-

methyltransferase (PNMT) mRNA expression analysis by semi-quantitative RT-PCR.
Tissue was collected 14 days after ovariectomy (OVEX), SHAM- surgery, ovariectomy +
estradiol replacement (OVEX +E2) or + vehicle treatment (OVEX +VEH). Upper Panel:
Ethidium bromide-stained agarose gel illustrating each PCR product (n = 3 per group).
The size of each product is listed in the left column. Lower Panel:

Densitometric

analysis of the relative signal intensities. Columns (lower panel) represent Mean ± SEM
of data from the 3 individual experiments in the upper panel.
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Figure 3.9
Effect of Estradiol-Replacement in Ovariectomized Rats on Adrenal Medullary Protein
Expression of Catecholamine Biosynthetic Enzymes

Immunoblot analysis of adrenal medullary protein levels for tyrosine hydroxylase (TH)
and phenylethanolamine N-methyltransferase (PNMT). Tissue was collected 14 days
after ovariectomy (OVEX); estradiol (E2)- or vehicle (sesame oil)-containing SILASTIC
capsules were implanted at the time of surgery.

Upper Panel:

20 µg of adrenal

medullary protein samples were separated by SDS-PAGE (n = 3 per group) and
subjected to immunoblot analysis with rabbit anti TH or rabbit anti PNMT in a dilution of
1:1000 for 1 hr. The size of the product is listed in the left column. Lower Panel:
Densitometric analysis of the relative signal intensities. Columns (lower panel) represent
Mean ± SEM of data from the 3 individual experiments in the upper panel.
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Figure 3.10
Effect of 48 hr Estradiol Treatment on Basal and Agonist-Induced Ca2+ Transients in
Rat Chromaffin Cells

Cells were exposed to either vehicle or 10 nM estradiol (E2) for 48 hr prior to analysis.
Data are expressed as peak intracellular Ca2+ concentration achieved in response to
either 50 µM nicotine (NIC) or to 60 mM KCl. Columns represent Mean ± SEM of data
from 3 separate isolations.
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Figure 3.11
Effect of Acute Estradiol Treatment on Agonist-Induced Ca2+ Transients in Rat
Chromaffin Cells: Dose Dependent Effects and Representative Trace

Upper Panel: Dose-dependent effects of acute estradiol (E2) exposure on nicotine
(NIC)-induced intracellular Ca2+ transients in rat chromaffin cells. Cells were exposed to
various concentrations of E2 for 3 min prior to stimulation with a 15-sec pulse of 50 µM
NIC.

Data are expressed as a percent of a control NIC-induced Ca2+ transient

measured prior to E2 treatment. Lower Panel: Representative trace of intracellular Ca2+
responses to 15-sec pulses of 50 µM NIC (arrows) prior to E2 exposure, after 3 min
exposure to 10 µM E2, and after 10 min washout of E2.

Columns (upper panel)

represent Mean ± SEM of data from 3-4 separate isolations. * P<0.001 compared to
control transients
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Figure 3.12
Effect of Acute Estradiol Treatment on Agonist-Induced Ca2+ Transients in
Rat Chromaffin Cells: Time Dependent Effects and
Nicotine vs KCl-Induced Transients

Upper Panel: Time dependent effects of acute estradiol (E2) exposure on nicotine
(NIC)-induced intracellular Ca2+ transients in rat chromaffin cells. Cells were exposed to
either 1 or 10 µM concentrations of E2 for 3, 10, and 20 min prior to stimulation with a
15-sec pulse of 50 µM NIC. Data are expressed as a percent of a control NIC-induced
Ca2+ transient measured prior to E2 treatment. Lower Panel:

Effect of acute E2

exposure on NIC- and KCl-induced intracellular Ca2+ transients in rat chromaffin cells.
Cells were exposed to either 10 or 50 µM concentrations of E2 for 3 min prior to
stimulation with a 15-sec pulse of 50 µM NIC or 60 mM KCl. Columns represent Mean
± SEM of data from 3-4 separate isolations. * P<0.001 compared to control transients.
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Figure 3.13
Effect of 48 hr Estradiol Treatment on Basal and Agonist-Induced cAMP Accumulation
in H295R Cells

Cells were exposed to either vehicle or 10 nM estradiol (E2) for 48 hr prior to incubation
(10 min) with PACAP-27 (PAC 27; 10-7 M).

All incubations included the

phosphodiesterase inhibitor Ro20-1724 (25 µM). Columns represent Mean ± SEM of
duplicate determinations from 3 experiments. * P<0.05 compared to vehicle-treated
cells.
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Figure 3.14
Effect of Acute Estradiol Treatment on Basal and Agonist-Induced cAMP Accumulation
in H295R Cells

Cells were exposed to either vehicle or 10 nM estradiol (E2) for 10 min prior to
incubation (10 min) with PACAP-27 (PAC 27; 10-7 M). All incubations included the
phosphodiesterase inhibitor Ro20-1724 (25 µM). Columns represent Mean ± SEM of
duplicate determinations from 3 experiments.
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Figure 3.15
Effect of Estradiol-Replacement in Ovariectomized Rats on Hypoglycemia-Induced
Changes in Renal Sympathetic Nerve Activity

Experiments were conducted 14 days after ovariectomy (OVEX); estradiol (E2)- or
vehicle (sesame oil)-containing SILASTIC capsules were implanted at the time of
surgery. A renal sympathetic nerve fiber was isolated and placed on a stainless steel
electrode and stabilized with a silicon-based impression material. Renal sympathetic
nerve activity (RSNA) was recorded for 20 min prior to insulin to calculate baseline
activity. Data are expressed as a percent of the baseline shown as the solid line at
100%. Circles represent Mean ± SEM of data from 3 separate experiments. * P<0.05
compared to OVEX group. Ψ P< 0.05 compared to baseline.
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Figure 3.16
Effect of Estradiol-Replacement in Ovariectomized Rats on
Plasma Epinephrine Clearance Rates

Plasma epinephrine (EPI) concentrations before and during EPI infusions at a rate of
600, 1500, and 3000 pmol/kg/min (arrows). An arterial blood sample (0.6 mL) was
taken prior to the start of the infusion and after 30 min of infusion with each dose.
Experiments were conducted 14 days after ovariectomy (OVEX); estradiol (E2)- or
vehicle (sesame oil)-containing SILASTIC capsules were implanted at the time of
surgery.

Circles represent Mean ± SEM of data from 4-5 separate experiments.

*P<0.05 compared to OVEX group.
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Figure 3.17
Effect of Acute Estradiol Treatment in Ovariectomized Rats on Hypoglycemia-Induced
Increases Plasma Epinephrine Concentration

Experiments were conducted 14 days after ovariectomy. 17β-Estradiol (E2; 150 µg/kg)
was administered IV over a 2 min period 30 min prior to insulin, followed by a constant
infusion (75 µg/kg/hr) for the duration of the experiment.

Insulin (0.25 U/kg) was

administered intravenously as a bolus at time 0. Arterial blood samples (0.6 mL) were
taken immediately prior to and 30 and 60 minutes after the insulin. Upper Panel: Effect
of insulin on plasma glucose concentrations. Lower Panel: Effect of hypoglycemia on
plasma epinephrine (EPI) concentrations. Circles (upper panel) and columns (lower
panel) represent Mean ± SEM of data from 6-7 separate experiments.
compared to vehicle-treated group.
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Figure 3.18
Effect of Acute Estradiol Treatment in Ovariectomized Rats on Hypoglycemia-Induced
Changes in Heart Rate and Mean Arterial Blood Pressure

Upper Panel: Effect of hypoglycemia on heart rate. Lower Panel: Effect of hypoglycemia
on mean arterial blood pressure (MAP). Experiments were conducted 14 days after
ovariectomy. 17β-Estradiol (E2) or vehicle was administered IV over a 2 min period 30
min prior to insulin, followed by a constant infusion of the steroid for the duration of the
experiment.

Insulin was administered intravenously as a bolus at time 0. Circles

represent Mean ± SEM of data from 6-7 separate experiments.
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Figure 3.19
Effect of Gender on Hypoglycemia-Induced Increases in
Plasma Epinephrine Concentration

Experiments were conducted in 14 week-old male and female rats. Insulin (0.25 U/kg)
was administered intravenously as a bolus at time 0. Arterial blood samples (0.6 mL)
were taken immediately prior to and 30 and 60 minutes after the insulin. Upper Panel:
Effect of insulin on plasma glucose concentrations. Lower Panel: Effect of hypoglycemia
on plasma epinephrine (EPI) concentrations. Circles (upper panel) and columns (lower
panel) represent Mean ± SEM of data from 6-7 separate experiments. * P < 0.01
compared to male group.
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Figure 3.20
Effect of Gender on Hypoglycemia-Induced Changes in
Heart Rate and Mean Arterial Blood Pressure

Upper Panel: Effect of hypoglycemia on heart rate. Lower Panel: Effect of hypoglycemia
on mean arterial blood pressure (MAP). Experiments were conducted in 14 week-old
male and female rats. Insulin was administered intravenously as a bolus at time 0.
Circles represent Mean ± SEM of data from 6-7 separate experiments.
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Chapter 4: Discussion
Effects of Estradiol
A number of clinical studies have reported that stress-induced increases in
plasma epinephrine levels are decreased in post-menopausal subjects receiving
estrogen-replacement therapies (Del Rio et al., 1993; Komesaroff et al., 1999; Ceresinsi
et al., 2000; Sandoval et al., 2003). Estrogen supplementation even attenuates mental
stress-induced increases in plasma epinephrine in hypoganadal, elderly men
(Komesaroff et al., 2002). While these data illustrate that administration of exogenous
estradiol suppresses the adrenal medullary response to stress, it remains to be
established whether normal circulating levels of estradiol can modulate this response,
due to the fact that the levels and types of estrogen administered in these replacement
therapies were typically non-physiologic and were almost always administered orally.
Also, these reports were limited to a cohort of aging subjects, and most often investigate
the effect of replacement therapies in women whose circulating estradiol concentrations
have been severely depleted for months or even years. In this context, the timing of
estradiol replacement after the loss of the steroid (by ovariectomy) can affect final
outcomes. For example, the ovariectomy-induced rise in circulating luteinizing hormone
(LH) level in rats is abolished by estradiol replacement at the time of ovariectomy, while
estradiol replacement three weeks after ovariectomy reduces the serum LH level by
only 50% (King et al., 1987). The same study also reported that luteinizing hormonereleasing hormone quantities in the medial basal hypothalamus are higher in
ovariectomized rats administered estradiol replacement at the time of surgery,
compared to rats that were estradiol replaced three weeks after ovariectomy. In order
to avoid these confounds, the primary goal of the present study was to assess the
adrenal medullary response to stress in young, but sexually mature rats in which
estradiol levels were controlled by ovariectomy and immediate estradiol replacement.
Our studies have established that physiological circulating levels of 17β-estradiol
suppress stress-induced increases in plasma epinephrine in the young adult, female rat.
This conclusion is based on two fundamental observations. First, insulin-induced
hypoglycemia increases plasma epinephrine concentration to a significantly greater
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extent in 14-day ovariectomized rats than in sham-operated controls. Second, and
perhaps more specifically, the rise in plasma epinephrine is significantly lower in
ovariectomized, estradiol-replaced rats than in vehicle-treated ovariectomized rats. This
replacement regime elicited plasma estradiol concentrations virtually identical to those
of sham-operated rats during the pro-estrous phase of the estrus cycle. Comparing
across groups, the rise in plasma epinephrine attained with 30 min of hypoglycemia in
the estradiol-replaced rats was, in fact, quite comparable to that of the sham-operated
controls, suggesting indirectly that the modulation of plasma catecholamine levels is
due to an effect of physiological levels of circulating estradiol alone and not in
combination with other ovarian steroids.
Insulin-induced hypoglycemia is a standard method used for assessing adrenal
stress responses, despite the fact that the mechanism by which insulin elicits an
increase in plasma catecholamines is still not completely understood. While there is
evidence that insulin can directly stimulate epinephrine release from the adrenal
medulla in vitro (Macho et al., 1996), the preponderance of evidence suggests that the
in vivo response requires a centrally-mediated neuronal activation. For example, it has
been shown that adrenal denervation inhibits the hypoglycemia-induced increases in
both plasma epinephrine concentration (Khalil et al., 1986) and adrenal medullary
tyrosine hydroxylase gene expression (Vietor et al., 1996).

Increases in plasma

epinephrine are also attenuated in brain/neuron specific insulin receptor knockout mice
(Fisher et al., 2005).
Despite this uncertainty surrounding the mechanism, there are several
advantages in utilizing an insulin-induced hypoglycemic model of stress. Firstly, it is
well established that hypoglycemia consistently increases plasma epinephrine levels in
both experimental animals (Fujino and Fujii, 1995; Vollmer et al., 1997; Drake et al.,
1998) and humans (Diamond et al., 1993; Davis et al., 2000; Sandoval et al., 2003;
Heise et al., 2004). Secondly, in contrast to other stress paradigms such as footshock
(Weinstock et al., 1998), hypoxia (Bloom et al., 1977), and cold (Kanayama et al.,
1999), the magnitude of the epinephrine increase in response to hypoglycemia is insulin
dose-dependent. A third advantage of this model is that it can be utilized reliably in both
conscious (Goldstein et al., 1993; Vollmer et al., 1997; Batista et al., 2005; Fisher et al.,
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2005) and anesthetized (Mokuda and Sakamoto, 1994; Lamarche et al., 1995; Drake et
al., 1998) experimental animals. We selected the anesthetized model for use in the
present studies for a number of reasons. For example, anesthesia decreases many of
the environmental confounds that can affect the stress response. Second, this model
eliminates the need for multiple survival surgeries.

Finally, from a productivity

perspective, the turnover rate of chronically instrumented, conscious animal studies is
much slower than that of anesthetized studies.
The utilization of an anesthetized model in these studies was, however, also
precipitated by our early work which focused on the development of a classical
conditioning paradigm so that stress responses in the conscious female rat could be
assessed.

Using a paradigm modified from Randall et al. (1994), rats were first

habituated to handling and restraint in a cloth sock for 1-2 days, after which each rat
was exposed for 1 week to 5 trials per day of a 15-second pulsed tone followed by a 0.5
second, 0.4 mAmp tail shock. On the day of the experiment, the rats were placed in the
sock and exposed to 1 tone + shock.

This paradigm has been shown to evoke

immediate, short-duration increases in sympathetic nerve activity (Randall et al., 1994;
Brown et al., 1999) and in principle, should have resulted in epinephrine secretion from
the adrenal medulla. However, this paradigm failed to elicit even marginal increases in
plasma epinephrine levels, suggesting that the adrenal medulla does not secrete
epinephrine in response to this model of stress.
The estrogen-dependent suppression of hypoglycemia-induced increases in
plasma epinephrine could, in theory, be due to either decreased adrenal medullary
secretion and/or increased peripheral clearance of epinephrine. We do have data to
support the concept that estradiol replacement suppresses adrenal medullary secretion
in ovariectomized rats.

This conclusion is based on measurements of epinephrine

concentration from the adrenal vein during hypoglycemia.

Our approach in these

experiments was a modification of a standard method used to assess adrenal
catecholamine output (Engeland and Gann, 1989; Gaumann et al., 1990; Vollmer et al.,
2000; Lamouche and Yamaguchi, 2001), which allows blood to flow from the vein for
the duration of the experiment while donor blood is infused through a peripheral vein. In
order to minimize confounds associated with continuous bleeding and donor
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replacement, blood was collected over just one 6 min period after 24 min of
hypoglycemia in the present study. The epinephrine measured during this time should
represent peak adrenal output because both the hypoglycemia-induced decrease in
blood glucose concentration and rise in sympathetic nerve activity are maximal at this
time. Ideally, to confirm this assumption these experiments should be repeated to allow
sampling at other post-insulin time points as well as to establish pre-insulin epinephrine
secretory levels. Recognizing the inherent limitations of this approach, considerable
time was initially invested on attempting to establish a method for the continuous
measurement of adrenal epinephrine output using in vivo chronoamperometry. This
technique successfully detects and quantifies catecholamines in the brain (Freund et al.,
2003; Moxon et al., 2004; Burmeister et al., 2005; Glaser et al., 2005). With assistance
from Dr. Greg Gerhardt and members of his laboratory, both a Nafion-coated carbon
fiber electrode and a ceramic-based multisite electrode were successfully introduced
into the adrenal vein and the adrenal medulla. However, both electrodes failed to detect
epinephrine at either site, due, at least in part, to the electrodes’ inability to oxidize
catecholamines in blood or highly vascularized tissue.
Subsequent experiments addressed the question of whether estradiol-dependent
suppression of the adrenal output of epinephrine was due to decreased synthesis
and/or secretion of epinephrine by the chromaffin cell. Green et al. (1999), initially
reported estrogen receptor-α (ERα) immunoreactivity in chromaffin cells of the female
but not male rat adrenal gland. The RT-PCR and immunoblot data in the present study
confirms and expands on this report, since ER-α message and protein expression and
estrogen receptor-β (ERβ) message can be detected in the female rat adrenal medulla,
albeit at considerably lower levels of expression than in the uterus and ovary
respectively.
Despite the probable existence of functional estradiol receptors in the medulla,
the present studies do not support the hypothesis that this steroid directly affects either
epinephrine biosynthesis in or secretion from the adrenal medulla. At the gene level,
semi-quantitative RT-PCR analysis revealed that mRNA levels for both tyrosine
hydroxylase (TH) and phenylethanolamine N-methytransferase (PNMT) are not different
in adrenal medullae taken from ovariectomized versus sham-operated animals or from
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estradiol- versus vehicle-replaced ovariectomized rats. At the protein level, neither TH
nor PNMT expression was modulated by estradiol treatment in ovariectomized rats.
There are, in fact, already a number of contradictory reports on the effects of
estradiol on catecholamine biosynthesis in the adrenal medulla. Recently, Serova et al.
(2005) have reported that TH mRNA levels are increased in ovariectomized rats treated
with estradiol benzoate for 16 days compared to vehicle-treated ovariectomized rats.
And while Kohler et al. (1975) have reported that 10 days of estrogen administration to
intact female rats increases TH activity, de Miguel et al. (1989) have reported that TH
activity is unaffected by estrogen treatment in ovariectomized rats. Additionally, it has
also been reported that TH activity is not different in the adrenal medulla of aged (22
months old) female rats compared to young (2 months old), but adrenal medullary
epinephrine content is greater in the aged rats (Fernandez-Ruiz et al., 1989).
With regard to secretion, acetylcholine released by the adrenal nerve stimulates
Na+ influx via nicotinic acetylcholine receptor-operated ion channels on the chromaffin cell
(Wada et al., 1985). The resultant depolarization activates voltage-gated Ca2+ channels
and results in a transient rise in intracellular free Ca2+ concentration, which is the primary
trigger for catecholamine exocytosis (Kilpatrick et al., 1982). Previous studies from our
laboratory

established

that

48

hr

exposure

to

the

synthetic

glucocorticoid

dexamethasone significantly potentiated agonist-induced intracellular Ca2+ transients in
isolated adrenal medullary chromaffin cells (Fuller et al., 1997a, b). In the present study,
48 hr exposure to a relatively physiologic concentration of estradiol (10 nM) had no
significant effect on nicotine-induced intracellular Ca2+ transients, suggesting, albeit
indirectly, that the effects of estradiol in vivo are not due to a suppression of agonistinduced Ca2+ signaling in, and as a consequence epinephrine secretion from, the
chromaffin cell.
While nicotinic acetylcholine receptor mediated Ca2+ signaling is the primary
stimulatory pathway in these cells, it is well-established that chromaffin cells also express
muscarinic acetylcholine receptors (Inoue and Kuriyama, 1991; Inoue and Imanaga,
1995), which, upon activation, can also directly stimulate catecholamine secretion from rat
the chromaffin cell (Finnegan et al., 1996).

There is evidence that the number of

muscarinic acetylcholine receptors is increased in the hippocampus of ovariectomized
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rats, and that this increase is abolished by estradiol treatment (Cardoso et al.; 2004),
therefore future studies should also investigate the effects of estradiol on muscarinicreceptor mediated contributions to secretion.
Although adrenal output and intracellular Ca2+ signaling are valid means by which
to assess stress-induced chromaffin cell secretion, cellular processes ‘downstream’ of
Ca2+ signaling were not directly examined in these studies. Previous studies from our
laboratory have determined nicotinic-induced catecholamine secretion in single cells by
carbon-fiber amperometry (Liu et al., 2001). One of the limitations of this approach is that
measurements can reliably only be compared within the same cell, making this technique
more appropriate for acute drug exposure studies. The effects of longer-term (ie. 48 hr)
exposure to a steroid (dexamethasone) on agonist-induced epinephrine secretion have
been assessed in populations of cells by HPLC (Fuller et al., 1997b), but this method
requires a large number of cells for each experiment and cell yields from rat adrenal
glands are typically too low for this type of analysis. However, while chronoamperometry
has not proven effective for measuring plasma concentrations of epinephrine, it may be
possible to utilize this approach to assess the effects of estradiol on secretion in vitro. Our
in vivo attempts at chronoamperometry gave us experience in calibrating carbon-fiber
electrodes for epinephrine in solution and it may be possible to use these types of
electrodes in order to measure secretion from a small number of cells.
A more global approach to examine the effects of estradiol on stimulus-secretion
coupling pathways in the adrenal medulla would be to utilize gene array technology.
However, our experience in this area was not very encouraging. In experiments to assess
the effects of age on gene expression in the adrenal medulla, the expression levels of 62
known genes were significantly increased and the expression levels of 67 known genes
were significantly decreased by a minimum of 1.5 fold in the adrenal medulla of aged
compared to young rats. However, none of the genes that were affected by age were
known to be particularly important in secretory signaling or biosynthetic pathways, even
though it is well established that both stress-induced plasma catecholamine levels
(McCarty 1986; Mabry et al., 1995) and expression of tyrosine hydroxylase (Voogt et al.,
1990; Tumer et al., 1992; 1997; Tumer and Larohelle, 1995) are significantly increased
with age.
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In contrast to the apparent lack of effect of circulating levels of estradiol on
chromaffin cell function discussed earlier, short-term exposure to high, presumably nonphysiologic levels of estradiol can suppress agonist-induced Ca2+ signaling in the
P

P

chromaffin cell. These data are fundamentally consistent with several previous reports
in which acute exposure to micromolar concentrations of estradiol significantly
depressed nicotinic receptor-triggered increases in intracellular Ca2+ concentration in
P

P

bovine chromaffin cells (Liu et al., 2002; Machado et al., 2002) and KCl-induced
transients in PC-12 cells (Kim et al., 2000). The present study demonstrated that 3 min
of exposure to estradiol is sufficient to dose-dependently suppress nicotine and KClinduced Ca2+ transients in rat chromaffin cells. The fact that the effect was both rapid
P

P

and reversible suggests that estradiol is acting non-genomically.

Although

catecholamine secretion was not measured in this study, previous work from our
laboratory has shown that a suppression of nicotine-induced intracellular Ca2+ transients
P

P

of this magnitude reduces nicotine-induced catecholamine secretion from porcine
chromaffin cells (Wagner et al., 1999). However, it has been reported that short-term
exposure to estrogens, including 17β-estradiol, has no effect on acetylcholine-induced
secretion from bovine chromaffin cells, while androgens inhibit agonist-induced
secretion (Dar and Zinder, 1997).
Due to the high concentrations of estradiol used, it is plausible that the acute
effects of estradiol on chromaffin cell signaling are non-cell specific. The present study
has demonstrated that acute exposure to a high concentration of estradiol does not
affect function in every adrenal cell type. The NCI-H295R cell line was derived from
human adrenocortical cells. These cells retain the ability to secrete mineralocorticoids,
glucocorticoids, and adrenal androgens (Rainey et al., 1994), and like primary adrenal
cortical cells, express pituitary adenylate cyclase-activating polypeptide (PACAP)
receptors that, when activated, stimulate cAMP synthesis and the subsequent release
of aldosterone and/or cortisol (Bodart et al., 1997; Haidan et al., 1998).

Acute

exposure to a high concentration of estradiol did not affect PACAP-mediated cAMP
accumulation in these cells. In contrast, 48 hr exposure to a physiologic concentration
of estradiol significantly attenuated PACAP-induced increases in cAMP accumulation in
this cell line. While it is difficult to correlate data between primary cultures of cells and a
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cell line, as well as between species, these data do suggest that both the acute and
long-term effects of estradiol on intracellular signaling processes are cell-type specific.
Given that acute treatment with estradiol attenuated agonist-induced Ca2+
transients in the chromaffin cell, epinephrine secretion should also be suppressed,
which would result in decreased stress-induced rises in plasma epinephrine levels in
vivo. Using the hypoglycemic stress model, we tested this hypothesis and have now
shown that an acute infusion of supra-physiological levels of estradiol does suppress
the insulin-induced rise in plasma epinephrine in ovariectomized rats. It should be noted
however, that the overall effect on plasma epinephrine levels is relatively small given
the large increase in plasma estradiol levels that occurred with this infusion paradigm.
Therefore, it is unlikely that a physiological increase in estradiol could occur that would
be of the magnitude needed to elicit an acute effect on circulating epinephrine levels.
The studies to this point do not support the concept that the estradiol-dependent
suppression of stress-induced adrenal epinephrine output is due to modulation of either
epinephrine biosynthesis or stimulus-secretion coupling in the chromaffin cell.
Therefore, subsequent experiments addressed the possibility that estradiol can
modulate stress-induced increases in sympathetic nerve activity, which is the initial
trigger for catecholamine secretion from the adrenal medulla. Although previous reports
have demonstrated that intravenous administration of supra-physiologic concentrations of
estrogen can rapidly suppress both renal and splanchnic nerve activity in ovariectomized
rats (He et al., 1998), and that chronic estrogen treatment can affect sympatheticallymediated baroreflex sensitivity (He et al., 1999; Pamidimukkala et al., 2003),

in the

present study, hypoglycemia-induced increases in nerve activity were actually greater in
the estradiol-replaced ovariectomized rats compared to vehicle-treated ovariectomized
rats. Clearly these data are not consistent with the concept that estradiol suppresses
epinephrine secretion by modulating neural input, since this increased nerve activity
should elicit a greater epinephrine response to stress.
One limitation of these data is that recordings were made from the more easily
accessible renal nerve, while secretion is predominately regulated by the activity of the
splanchnic/adrenal nerve. Therefore, the activity of these nerves during hypoglycemia
should also be examined in order to fully assess the effect of estradiol on neural input to

96

the adrenal medulla.

This requirement is further supported by the fact that a given

stimulus can induce a diverse pattern of sympathetic responses. For example, Scislo et
al. (2001) demonstrated that stimulation of A2A receptors increased adrenal nerve activity,
decreased renal nerve activity, and did not affect lumbar nerve activity. This same group
also reported that A1 receptor stimulation increased the activity of the adrenal, renal, and
lumbar nerves, but the magnitude of the increase was greatest in the adrenal nerve and
lowest in the lumbar nerve. In addition, it has been reported that estrogen potentiates
presynaptic function in cultured hippocampal neurons (Yokomaku et al., 2003) and
enhances glutamate receptor-mediated excitatory postsynaptic potential (Foy et al., 1999);
but there is little published research investigating the effects of physiological
concentrations of estradiol on nerve properties such as conductivity, pre- and postsynaptic function and synapse plasticity.

The information from such studies would

certainly offer insight into how estrogen may modulate the neural input to the adrenal
medulla.
In review of the results thus far, the reduced adrenal output of epinephrine in
estradiol-replaced, ovariectomized rats is consistent with the observed depressive
effects of physiological levels of estradiol on the hypoglycemia-induced increases in
plasma epinephrine concentration.

The mechanism(s) underlying the suppressive

effects of estradiol on adrenal medullary secretion remain to be defined. A final series
of experiments assessed whether the difference in plasma epinephrine concentration
during hypoglycemia may also be attributed to differential rates of plasma
catecholamine clearance. To assess the effects of estradiol on plasma epinephrine
handling, 30 min sequential intravenous infusions of epinephrine (600, 1500, and 3000
pmol/kg/min) were administered in vehicle and estradiol-treated ovariectomized rats. At
all epinephrine infusion rates, plasma epinephrine concentrations were lower in the
estradiol-replaced

ovariectomized

group

compared

to

the

vehicle-treated

ovariectomized rats after each infusion, suggesting that the clearance of epinephrine
from the circulation was higher in these animals.
However, these data are not consistent with the majority of available information
which suggests that estrogen negatively regulates both catecholamine metabolism and
cellular reuptake. For example, the activity of catechol-O-methyltransferase (COMT),
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the main enzyme responsible for the metabolism of catecholamines, is at its lowest level
in the female rat brain and adrenal gland during the pro-estrous phase of the estrous
cycle (Parvez et al., 1978), the period of highest circulating estradiol concentration
(Smith et al., 1975). Also, both the gene expression and the activity of COMT are
down-regulated by physiologic concentrations of estradiol in MCF-7 cells (Xie et al.,
1999; Jiang et al., 2003).

It has also been reported that estradiol can affect nor-

epinephrine transporter function in bovine chromaffin cells, suppressing cellular
reuptake (Toyohira et al., 2003).

Consequently, these effects on metabolism and

reuptake should elevate plasma epinephrine levels.

Effects of Gender
As noted earlier in the discussion, estradiol supplementation can also reduce the
epinephrine response to stress in men (Komesaroff et al., 2002).

These data are

consistent with both clinical (Diamond et al., 1993; Davis et al., 2000; Galassetti et al.,
2001) and basic science (Drake et al., 1998) studies which have demonstrated that
stress-induced increases in plasma catecholamines are lower in females than in males.
In contrast, however, the data from our experiments on gender are diametrically
opposed to these reported observations, since hypoglycemia-induced increases in
plasma epinephrine levels are greater in female rats compared to age-matched males.
Our data are, however, consistent with at least one published report, which
demonstrated that the extent and duration of both the corticosterone and epinephrine
response to foot-shock is also higher in females compared to age-matched males
(Weinstock et al, 1998).

Summary
The studies contained in this dissertation have clearly demonstrated that
physiological circulating levels of estradiol suppress stress-induced increases in plasma
epinephrine concentration. This suppression may be due to both a reduction in adrenal
medullary epinephrine secretion and an increase in plasma clearance of the
catecholamine. However, the specific mechanism(s) underlying these effects have yet
to be established.

For example, while the decreased adrenal vein epinephrine
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concentration is consistent with a reduction in epinephrine secretion, our data suggest
that this effect could not be attributed to decreased biosynthesis, attenuation of
intracellular Ca2+ signaling, or decreased sympathetic nerve activity. Additionally, while
epinephrine clearance is markedly increased in estradiol-replaced rats, available data in
the literature do not support that this increase could be attributed to the increased
activity of catecholamine metabolizing enzymes such as COMT.

We have also

confirmed previous in vitro reports that short-term exposure to high concentrations of
estradiol can attenuate agonist-induced Ca2+ signaling in the chromaffin cell and shown
for the first time that acute exposure to high, presumably non-physiological, levels of
estradiol can suppress stress-induced increases in plasma epinephrine in vivo.

Copyright © Julye M. Adams 2005
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